Applications of molecular biology and biotechnology: antibody therapy of sepsis (Q41050793)

26 September 2017

1 reference

title

Applications of molecular biology and biotechnology: antibody therapy of sepsis (English)

1 reference

26 September 2017

0 references

0 references

1 reference

Wheeler AP

1

1 reference

PubMed ID

8727029

26 September 2017

Bernard GR

series ordinal

2

1 reference

26 September 2017

1 June 1996

1 reference

26 September 2017

Journal of Critical Care

1 reference

26 September 2017

11

1 reference

26 September 2017

2

1 reference

26 September 2017

77-94

1 reference

Prediction, prevention, and mechanism of early (anaphylactic) antivenom reactions in victims of snake bites

26 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Comparison of the purity and efficacy of affinity purified avian antivenoms with commercial equine crotalid antivenoms

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Antibodies to Core Lipopolysaccharide Determinants: Absence of Cross-reactivity with Heterologous Lipopolysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Allergic histories and reactions of patients treated with digoxin immune Fab (ovine) antibody. The Digibind Study Advisory Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid.

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin.

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5.

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Studies of an antiendotoxin antibody in preventing the physiologic changes of endotoxemia in awake sheep.

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Protective effects of E5, an antiendotoxin monoclonal antibody, in the ovine pulmonary circulation

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Efficacy of anti-endotoxin monoclonal antibody E5 alone or in combination with ciprofloxacin in neutropenic rats with Pseudomonas sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and nonbacteremic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected, serious, gram-negative sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Effects of anti-lipid A human monoclonal antibody on lipopolysaccharide-induced toxicity to the kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram-negative shock.

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Efficacy of antilipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudomonas sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Monoclonal antibody to TNF in severe septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Monoclonal antibody to tumor necrosis factor alpha attenuates cardiopulmonary dysfunction in porcine gram-negative sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Administration of tumor necrosis factor α (TNFα) inhibitors after exposure to TNFα prevents development of the maximal biological effect: An argument for clinical treatment with TNFα inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Monoclonal antibodies to human tumor necrosis factor α: In vitro and in vivo application

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

Anti-tumor necrosis factor-alpha prevents decreased ventricular contractility in endotoxemic pigs.

1 reference

https://api.crossref.org/works/10.1016%2FS0883-9441%2896%2990023-4

7 January 2021

10.1016/S0883-9441(96)90023-4

Identifiers

DOI

1 reference

26 September 2017

1 reference

PubMed ID

8727029